^
Association details:
| Biomarker: | ERBB2 G778A + CCNE1 amplification |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) + adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
327/2-Antitumor efficacy of trastuzumab deruxtecan in combination with adavosertib in HER2-expressing Cyclin E amplified gastroesophageal cancers
Published date:
03/09/2022
Excerpt:
T-DXd induced durable tumor regression in two HER2 amplified and HER2 overexpressing gastroesophageal PDX cancer models with HER2 amplification/3+ overexpression and concomitant cyclin E amplification/expression. Adavosertib enhanced the antitumor activity of T-DXd in two HER2 low, cyclin E amplified gastroesophageal cancer PDX models (one with an ERBB2 G778A mutation).
